News Sanofi scores in MS with CD40 antibody frexalimab Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
